Business Description
Ionis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US4622221004
Total Employee Number:
1,402Compare
Compare
Traded in other countries / regions
IONS.USA0JDI.UKISI.Germany1IONS.ItalyIONS.Mexico Index Membership
Russell 1000Russell 3000 IPO Date
1991-05-17Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.3 | |||||
Equity-to-Asset | 0.15 | |||||
Debt-to-Equity | 3.6 | |||||
Debt-to-EBITDA | -3.34 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.21 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.5 | |||||
3-Year EBITDA Growth Rate | -2 | |||||
3-Year EPS without NRI Growth Rate | -0.9 | |||||
3-Year FCF Growth Rate | 0.7 | |||||
3-Year Book Growth Rate | -9.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 30.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.75 | |||||
9-Day RSI | 36.71 | |||||
14-Day RSI | 41.35 | |||||
3-1 Month Momentum % | -23.09 | |||||
6-1 Month Momentum % | -23.61 | |||||
12-1 Month Momentum % | -7.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.33 | |||||
Quick Ratio | 2.28 | |||||
Cash Ratio | 1.92 | |||||
Days Inventory | 382.53 | |||||
Days Payable | 622.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -6.7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.14 | |||||
Operating Margin % | -68.03 | |||||
Net Margin % | -64.76 | |||||
EBITDA Margin % | -54.33 | |||||
FCF Margin % | -64.93 | |||||
OCF Margin % | -56.8 | |||||
ROE % | -106 | |||||
ROA % | -17.7 | |||||
ROIC % | -43.11 | |||||
3-Year ROIIC % | 4.07 | |||||
ROC (Joel Greenblatt) % | -98.42 | |||||
ROCE % | -22.39 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 10.46 | |||||
PB Ratio | 21.03 | |||||
Price-to-Tangible-Book | 21.03 | |||||
EV-to-EBIT | -18.19 | |||||
EV-to-Forward-EBIT | -19.62 | |||||
EV-to-EBITDA | -18.65 | |||||
EV-to-Forward-EBITDA | -20.75 | |||||
EV-to-Revenue | 10.13 | |||||
EV-to-Forward-Revenue | 6.57 | |||||
EV-to-FCF | -15.6 | |||||
Price-to-GF-Value | 1.16 | |||||
Price-to-Median-PS-Value | 1.04 | |||||
Earnings Yield (Greenblatt) % | -5.5 | |||||
FCF Yield % | -6.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IONS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ionis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 874.049 | ||
| EPS (TTM) ($) | -3.46 | ||
| Beta | 0.8197 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 0.75 | ||
| Volatility % | 70.06 | ||
| 14-Day RSI | 41.35 | ||
| 14-Day ATR ($) | 2.311031 | ||
| 20-Day SMA ($) | 59.478 | ||
| 12-1 Month Momentum % | -7.28 | ||
| 52-Week Range ($) | 50.005 - 86.74 | ||
| Shares Outstanding (Mil) | 166.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ionis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ionis Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 170 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-25 08:30 | In 170 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 169 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 11:30 | In 51 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 50 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-16 07:45 | In 8 days | ||
| 21st Annual Wells Fargo Healthcare Conference | 2026-09-10 08:45 | In 2 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | 55.30 (-2.23%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 55.30 (-2.23%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 08:40 | 74.58 (-0.25%) |
Show
Entries
Ionis Pharmaceuticals Inc Frequently Asked Questions
What is Ionis Pharmaceuticals Inc(IONS)'s stock price today?
The current price of IONS is $55.94. The 52 week high of IONS is $86.74 and 52 week low is $50.01.
When is next earnings date of Ionis Pharmaceuticals Inc(IONS)?
The next earnings date of Ionis Pharmaceuticals Inc(IONS) is 2026-10-29 Est..
Does Ionis Pharmaceuticals Inc(IONS) pay dividends? If so, how much?
Ionis Pharmaceuticals Inc(IONS) does not pay dividend.
Guru Commentaries on NAS:IONS
Artisan Partners
Bullish
2026 Q2
ARTSX APDSX APHSX MCommentary 0726 vR
What the manager wrote
Ionis Pharmaceuticals is a biotechnology company specializing in RNA-targeted therapies for patients with significant unmet medical needs. The company is transitioning toward commercializing more of its own medicines, allowing it to potentially capture greater long-term value from its innovation. Recent results exceeded expectations, supported by stronger-than-expected commercial performance, while management reaffirmed its expectation of reaching cash flow breakeven in 2028. We continue to see attractive long-term opportunities across the company's commercial portfolio and pipeline.
2025 Q3
Tweedy Browne
· 93 holdings
What the manager wrote
Ionis Pharmaceuticals, a biotechnology company held in three of our four Funds, was another strong contributor following encouraging clinical results that helped renew investor confidence in its research pipeline. This positive momentum indicates a robust outlook for the company, suggesting that its innovative approaches in drug development are gaining traction in the market. The renewed investor confidence reflects the potential for Ionis to capitalize on its research advancements, positioning it favorably within the biotechnology sector.
Press Release
Articles on Ionis Pharmaceuticals Inc
Headlines
See More- 1
Sep 08, 2026
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
Seeking Alpha • 9:26am
Sep 04, 2026
Ionis Pharmaceuticals falls after Pelacarsen fails key Phase 3 heart trial
Seeking Alpha • 4:00pm
Sep 03, 2026
Ionis gains approval of zilganersen for Alexander disease
Seeking Alpha • 5:57pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers